Publications
-
Randomized Trial of Tumor Lysate Particle Only Vaccine vs. Tumor Lysate Particle-loaded, Dendritic Cell Vaccine to Prevent Recurrence of Resected Stage III/IV Melanoma: 36-MonthAnalysis - Society for Immunotherapy of Cancer
November 6, 2021
Journal for ImmunoTherapy of Cancer | Carpenter, et al.
-
Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-loaded, Dendritic Cell (TLPLDC) Vaccine to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIaTrial
October 10, 2021
Carpenter et al.
-
American Society of Clinical Oncology - The influence of harvest method on dendritic cell function and clinical outcomes in a randomized trial of a dendritic cell vaccine to prevent recurrences in high-risk melanoma
June 9, 2021
Journal of Clinical Oncology | Adams et al..
-
Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis
May 4, 2021
Cancer Medicine | Chick et al.
-
American Society of Clinical Oncology - Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
May 12, 2020
Journal of Clinical Oncology | Chick, et al.
-
New List IAmerican Society of Clinical Oncology - Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanomatem
June 8, 2019
Journal of Clinical Oncology | Hickerson, et al.
-
American Society of Clinical Oncology - Prospective, randomized, double-blind, placebo controlled, Phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected Stage III or IV melanoma patients
June 16, 2018
-
Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors
May 9, 2018
Vaccine | Herbert, et al.
-
Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine
February 7, 2018
Immunotherapy | Hardin et al.